Metformin activated the AMPK, thereby inhibiting the immunosuppressive function of MDSCs and delaying the tumor progression by inhibiting immune-related NF-κB and JAK-STAT pathways [174, 176, 177]. This evidence concerns the gene SOAT1 and neoplasm.